FiercePharma  Jun 18  Comment 
Here’s some irony for you: Pharma creative award submissions to the Cannes International Festival of Creativity are at a record low, but a bigger-than-ever lineup of pharma companies made the Lions Health short list.
FiercePharma  Jun 14  Comment 
Another day, another approval for Merck immuno-oncology star Keytruda. On Wednesday, the drug picked up an FDA green light to treat patients with a rare type of non-Hodgkin lymphoma whose cancer has come back after two or more prior lines of...
FiercePharma  Jun 14  Comment 
Sanofi figures PD-1 checkpoint inhibitors beat their PD-L1-targeting rivals. And that’s one reason it thinks its own PD-1, cemiplimab, can carve a decent niche in lung cancer, a field where it’ll be sixth to market and where Merck’s Keytruda...
FiercePharma  Jun 13  Comment 
Merck’s Keytruda has a new approval, and with it, immunotherapy has moved into a new frontier. With a Tuesday FDA green light for patients whose disease has worsened on or after chemotherapy, Keytruda became the first checkpoint inhibitor to win...
FiercePharma  Jun 12  Comment 
Merck has been fighting to take its appeal in the yearslong Fosamax product liability litigation to the Supreme Court, so when its opponents filed a brief urging the court to ignore the company's appeal, Merck fired back. If it succeeds, the...
FiercePharma  Jun 12  Comment 
Shingrix may not make it on the top five best-selling vaccines list in 2024, but a diversified portfolio will still secure GlaxoSmithKline the lead position in the vaccine industry at that time, followed by Merck & Co., Sanofi, Pfizer and a dark...


Merck & Co. (NYSE:MRK) is one of the largest pharmaceutical companies in the world, producing a wide assortment of medications. The company bought Schering-Plough (SGP) in 2009 to become one of the three largest pharmaceutical companies.

Merck faces many of the challenges that face all pharmaceutical companies, including issues surrounding patent expiration and FDA approval. In addition, there is growing pressure in the US and abroad to lower the price of medication. [1]

BTW, here are some of my personal preefrences you might be interested: (1) Prefer load package before utilities, because I have some use-defined utilities scripts which require certain packages to be loaded(2) utilities folder: my utilities scripts are too much to put into single file. I used to dividing them by functionalities(3) data.files.filter: most of time, I don't wanna load all data but I would like to keep them in the same folder. I plan to add a data.files.filter in global.yaml likedata.files.filter: grep(format(prevBizday(),'%y%m%d'), dir( data'), value=T) then, use parse(text=data.files.filter) within load.project()At this moment, I modified your source code to create customized template, and I sincerely appreciate your great work to save us much time and to maintain a more disciplined project.

Business Segments

For the fiscal year 2010, ended December 2010, Merck reported a total revenue of $45.99B and net earnings of $982M.[2]

Significant research and money-making drugs are related to long-term ailments such as cardiac disease, osteoporosis, and asthma. The company's segments are divided by therapeutic area, with the largest segments listed below.

Bone, Respiratory, Immunology and Dermatology (24.6% of 2010 Revenues)

This is the company's strongest segment with more drugs and nearly double the revenue of any other segment. This segment's blockbuster drugs (more than $1B in international sales) include: "'Singular"' for asthma, "'Remicade"' for inflammatory diseases, and "'Nasonex"' for the treatment of nasal allergies.

Cardiovascular (10% of 2010 Revenues)

The cardiovascular blockbuster drugs are: "'Zetia"', a cholesterol absorption inhibitor; and "'Vytorin"', a combination of Zetia and Zocor.

Diabetes and Obesity (7% of 2010 Revenues)

This segment's blockbuster drug is Januvia, a treatment for type 2 diabetes.

Diversified Brands (9% of 2010 Revenues)

The only blockbuster drug in this division is Cozaar/Hyzaar, which are used to treat hypertension.

Infectious Diseases (9% of 2010 Revenues)

The blockbuster drug in this division is Isentress for HIV treatment.

Oncology (4% of 2010 Revenues)

The main drug in this segment is Temodar used to treat certain types of brain tumors.

Vaccines (7.6% of 2010 Revenues)

The company's MMR Vaccine for mumps, measles, and rubella has blockbuster sales while Gardasil, for HPV prevention is nearly at blockbuster status.

Consumer Health Care ($1.3B in total sales for 2010)

In its acquisition of Schering-Plough, Merck inherited a $1.3 billion consumer health products division. One of the most well known brands is the Coppertone line of products, a variety of sun-block and insect repellent creams and sprays. Schering-Plough also markets the Dr. Scholl's line of foot care products, including shoe inserts, wart remover, and odor neutralizers for shoes. Consumer health care sales have remained relatively stable over the past several years; there are no major products slated to appear in the next few years, and there is no reason why demand for sunscreen would change drastically in the near future as well.

Research and Development ($11B on 2010)

Researching and developing new drugs is the single most important consideration when identifying the prospects of any pharmaceutical company. A successful drug pipeline is critical because former blockbusters losing patent protection must be constantly replaced by new viable drugs.

Trends and Forces

The main drivers in the pharmaceutical industry include product pipeline (new products in development), patent expiration (products becoming generic), and product diversification. The combination of these factors determine profits and forecasts, and are therefore very important in making investment decisions.

Merck BioVentures

BioVentures is the biologics manufacturing division of Merck established in 2008.[3] Currently, BioVentures is focused on creating generic versions of popular biologics such as Amgen's Enbrel and Roche's Avastin and Herceptin. While the generic drugs that Merck will produce in its BioVentures division will require substantial clinical trials, it is likely that the trial costs will be reduced compared to those of a novel biologic therapy. In addition, the added certainty of success -- both from a development and a market perspective -- for these follow-on drugs compared to novel biologic therapies add to the appeal of Merck's strategy.

Patent expirations

For a detailed discussion of brand name vs generic medication, see also Brand name vs Generic medications.

Due to Food and Drug Administration (FDA) regulations, pharmaceutical patents last 17 years, during which a pharmaceutical company has an exclusive right to manufacture a particular drug. After the patent expires, generic versions of the product can be produced and sold by competitors. Generic medication is cheaper than brand medication, and the lower cost is often a strong incentive for consumers to choose generic over brands. In addition, the presence of a generic alternative may prompt a decrease in the brand name medication price.

Tightening FDA Regulations

Beginning in 2009, the FDA implemented a series of reforms that include stricter monitoring of drug adverse events, more funding for the agency, stronger ability to force product recalls, more scientific expertise within the agency, more transparency. While the tightened regulations and increased transparency will eventually improve the overall quality of pharmaceutical products, companies will have to adjust to the stricter standards and stronger enforcement.[4]


Pharmaceuticals can face significant liabilities if a medication is later found to be defective or produce adverse reactions. Even though such adverse reactions are previously unknown and impossible to predict, damages claimed in such lawsuits are usually substantial. Depending on jurisdiction, the legal system may limit allowable damages.

For example, Vioxx was one of Merck's anti-arthritis drugs that gained widespread adoption for treating chronic pain. Up to 80 million patients were prescribed with Vioxx at its height. Soon after approval, several studies indicated that Vioxx increased the risk of heart attack over the placebo. Merck recalled the drug, but has faced several thousand lawsuits from patients who took the drug, which were eventually settled for $4.85B.

Comparison to Competitors

Major competitors to Merck include Novartis, Pfizer, and Bristol-Myers Squibb. All three are pharmaceutical powerhouses, some with compatible drugs. For example, Pfizer produces Lipitor, which is in direct competition with Zocor, and Novartis produces Diovan, which is in direct competition with Cozaar.

Competition in the pharmaceutical industry lies mostly in specific drug markets. For example, a new diabetes drug is not going to have any effect on an existing cholesterol drug, no matter how successful it is. As a result, financial data on the pharmaceutical companies do not tell the whole story. Instead, it may be more appropriate to analyze Merck's competitors by each drug market (See section on Major Drugs and Industry Trends).

  • Johnson & Johnson (HAN:JNJ) - Johnson & Johnson is a large diversified pharmaceutical company that competes with Merck.
  • Pfizer (PFE) - Pfizer is the largest pharmaceutical company in the world. It produces Lipitor that competes with Merck's Zocor.
  • Novartis AG (NVS) - Novartis is a large diversified pharmaceutical company that produces Diovan, which competes with Merck's Cozaar.
  • Abbott Laboratories (ABT) - Abbott Laboratories is a large diversified pharmaceutical company that competes with Merck.
  • Bristol-Myers Squibb Company (BMY) - Bristol-Myers Squibb is a large diversified pharmaceutical company that competes with Merck.
  • Eli Lilly and Company (LLY) - Eli Lilly is a large diversified pharmaceutical company that competes with Merck.
  • Amgen (AMGN) - Amgen is a large diversified pharmaceutical company that competes with Merck.
  • Gilead Sciences (GILD) - Gilead Sciences is a large diversified pharmaceutical company that competes with Merck.
  • AstraZeneca (AZN) - AstraZeneca is a large diversified pharmaceutical company that competes with Merck.
  • Roche Pharmaceuticals (RHHBY) - Roche Pharmaceuticals is a large diversified pharmaceutical company that competes with Merck.


  1. Merck 2008 10-K, Pg. 11
  2. MRK 2010 10-K, Item 6: Selected Financial Data, p. 45
  3. Merck Introduces New Strategy: BioVentures
  4. The FDA: A tough tonic
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki